Investigating NOvel VAluable bio-Therapeutics and Expression systems

Project coordinator
- Prof. Christopher Mark Smales - University of Kent - UK

Project leaders
- Dr. Andreas Schiermeyer - Fraunhofer Institute for Molecular Biology and Applied Ecology, Aachen - Germany
- Dr. Andrew Racher - Lonza Biologics plc, Slough - UK
- Prof. Paula Alves - Instituto de Tecnologia Química e Biológica, New University of Lisbon- Portugal
- Prof. Manuel Carrondo - Instituto de Biologia Experimental e Tecnológica, Oeiras - Portugal

The production of IgGs has revolutionized the biotech industry with products used for the treatment of
cancer and immune disorders. IgGs represent just one potential class of biotherapeutic and yet few other
classes (with potential to treat specific diseases) have been as well developed due to challenges in their
manufacture. Challenging new recombinant proteins (rPs) of commercial and clinical value include fusion
proteins (for novel disease targeting), IgA (the most abundant Ig isoform, for treatment of IgA
deficiencies, cancer) and secreted mucins (for disease therapy, vaccines). This project will develop new
animal (CHO) and plant (tobacco) cell and glycosylation expression technologies, and establish
bioprocesses, for the production of these difficult to express novel rPs that have the potential to open up
new targets and treatments that resist current therapies. The consortium will seek protection of IP rights
for the new technologies and to develop these with interested parties.